Biogenix Molecular, LLC
Biogenix Molecular, LLC
Miami, Florida, United States7 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of LY4257496 in Participants With Cancer (OMNIRAY) | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, breast disorder, breast neoplasm, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endometrium neoplasm, esophageal disorder, female reproductive system disorder, female reproductive system neoplasm, gastric neoplasm, intestinal disorder, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder, rectal disorder, skin disorder, stomach disorder, uterine disorder | Recruiting | Phase 1 | 2026-10-07 | NCT07114601 | |
| A Study of LY4337713 in Participants With FAP-Positive Solid Tumors | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, Pancreatic Intraductal Neoplasms, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, breast disorder, breast neoplasm, carcinoma, cholangiocarcinoma, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, esophageal disorder, female reproductive system disorder, female reproductive system neoplasm, gastric neoplasm, gonadal disorder, intestinal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, pancreas disorder, pancreatic neoplasm, rectal disorder, skin disorder, stomach disorder | Recruiting | Phase 1 | 2026-09-22 | NCT07213791 | |
| A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors | Head and Neck Neoplasms, Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, cervical adenocarcinoma, colorectal adenocarcinoma, head and neck cancer, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 1 | 2026-09-17 | NCT07020117 | |
| A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 1 | 2026-09-15 | NCT07581184 | |
| Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 3 | 2026-09-11 | NCT06056830 | |
| A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 2 | 2026-08-17 | NCT06842498 | |
| FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Metastatic Castration-resistant Prostate Cancer | Active, not recruiting | Phase 2 | 2026-04-08 | NCT06402331 |